NVIDIA collaborates with Eli Lilly to build an AI pharmaceutical supercomputer
NVIDIA (NVDA.US) announced on Tuesday that it has partnered with Eli Lilly (LLY.US) to establish a supercomputer for drug discovery using artificial intelligence.
Eli Lilly will utilize 1,016 DGX SuperPODs based on the NVIDIA Blackwell architecture and DGX B300 systems. This AI drug factory will train large biomedical foundational and cutting-edge models for drug discovery and development, and will provide related services on the TuneLab platform
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments